To include your compound in the COVID-19 Resource Center, submit it here.

Iressa gefitinib: Phase II data; marketed

In a Phase II study, previously untreated patients given 500 mg/day Iressa had a median survival

Read the full 163 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE